News
NTRB
2.790
-0.36%
-0.010
HOV, LTRX and ELDN among mid-day movers
Seeking Alpha · 6d ago
Nutriband Earnings Perspective: Return On Capital Employed
Benzinga · 05/04 14:51
Nutriband Inc. Reports Revenue Up 46% In Fiscal 2023; FY23 Revenue $2.08M Vs $1.4M YoY; EPS $(0.53) Vs $(0.80) YoY
Benzinga · 04/27 12:13
Pre-market Movers: VKTX, IMRX, OSCR, WISA, ITCI…
NASDAQ · 03/28 12:21
Nutriband Secured $2M Line of Credit Financing Facility to be Used for Commercialization of AVERSA(TM) Abuse-Deterrent Transdermal Technology
Benzinga · 03/28 11:47
BHC, ONVO and AMAM among healthcare gainers
Seeking Alpha · 02/15 16:09
Nutriband To File for Product Distribution Permit In South America With Ecuador's Health Register
Benzinga · 02/15 11:05
Nutriband to Begin Trading on Upstream App
Nutriband to Begin Trading on Upstream App
MT Newswires · 01/05 06:55
Nutriband Inc. To Dual List On Upstream
Benzinga · 12/30/2022 11:32
Nutriband Begins Production of AI Tape Brand, Launch Expected in Q1
Nutriband Begins Production of AI Tape Brand, Launch Expected in Q1
MT Newswires · 12/29/2022 07:10
Nutriband Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
RedChip Companies will air a new interview with Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) on The RedChip Money Report® on Bloomberg TV this Saturday, December 17, at 7 p.m. Eastern Time (ET).
ACCESSWIRE · 12/14/2022 11:00
Nutriband Inc.'s (NASDAQ:NTRB) CEO Compensation Looks Acceptable To Us And Here's Why
Shareholders may be wondering what CEO Gareth Sheridan plans to do to improve the less than great performance at...
Simply Wall St. · 12/03/2022 12:50
Nutriband Inc to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW)today announces that Gareth Sheridan, CEO, will be presenting at the RHK Capital Disruptive Growth Conference in New York City on Monday, December 5 at 10:20 AM.
ACCESSWIRE · 12/02/2022 12:00
Nutriband Receives Notice Of Issuance From The Canadian Intellectual Property Office For Its AVERSA(TM) Abuse Deterrent Transdermal Technology Patent
Benzinga · 12/01/2022 12:07
Nutriband Says it Received Canadian Patent for Drug Abuse Deterrent Product; Shares Rise
Nutriband Says it Received Canadian Patent for Drug Abuse Deterrent Product; Shares Rise
MT Newswires · 12/01/2022 10:00
Nutriband Secures Deal to Manufacture Fleur Marche's Wellness Patches; Shares Rise
Nutriband Secures Deal to Manufacture Fleur Marche's Wellness Patches; Shares Rise
MT Newswires · 10/27/2022 13:24
Nutriband To Manufacture Fleur Marché-Branded CBD Wellness Patches
Benzinga · 10/27/2022 11:45
Nutriband Inc. To Manufacture Fleur Marché-Branded Wellness Patches Under Exclusive Agreement
Benzinga · 10/27/2022 11:19
Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study For Sorrento Therapeutics On Lymphatic Etanercept Delivery In Rheumatoid Arthritis Patients With Results To Be Presented At The 2022 American College Of Rheumatology Conference
Benzinga · 10/26/2022 11:16
Nutriband And Kindeva Highlight Abuse-Deterrent Characteristics For AVERSA
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) with Kindeva Drug Delivery have demonstrated enhanced abuse deterrence kinetics of the Company's patented lead product, Aversa™ Fentanyl, an abuse-deterrent fentanyl
Benzinga · 10/04/2022 11:07
More
Webull provides a variety of real-time NTRB stock news. You can receive the latest news about Nutriband Inc through multiple platforms. This information may help you make smarter investment decisions.
About NTRB
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. The Company's lead product is its AVERSA technology, an abuse deterrent technology that can be incorporated into any transdermal patch to deter the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. Its first product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an existing generic fentanyl patch with its AVERSA technology to reduce the abuse and misuse of fentanyl patches. It is also focused on the development of additional products utilizing the AVERSA abuse deterrent transdermal technology, which include AVERSA Buprenorphine and AVERSA Methylphenidate. In addition, it is developing a portfolio of transdermal pharmaceutical products to deliver commercially available drugs or biologics that are typically delivered by injection. Its subsidiaries include 4P Therapeutics LLC and Pocono Pharmaceuticals Inc.